XTRA:1SXPLife Sciences
SCHOTT Pharma KGaA (XTRA:1SXP) Reports Higher Sales And Lower Earnings, Is It Fully Valued?
SCHOTT Pharma KGaA (XTRA:1SXP) reported third quarter 2026 results that combined higher sales with weaker profitability, giving investors fresh numbers on revenue momentum and margin pressure as of June 30.
See our latest analysis for SCHOTT Pharma KGaA.
The latest earnings come against a backdrop of strong recent momentum in SCHOTT Pharma KGaA's share price, with a 90 day share price return of 36.55% and a year to date share price return of 54.55%, even though the 1 year total shareholder...